Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

• ClinicalTrials.gov Identifier: NCT01442714
• Recruitment Status: Terminated
• First Posted: September 28, 2011
• Results First Posted: January 3, 2018
• Last Update Posted: January 3, 2018
• Sponsor: Stanford University
• Collaborator: Celgene Corporation
• Information provided by (Responsible Party): Bruno C. Medeiros, Stanford University

Study Description

Brief Summary:

The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and lenalidomide.

Condition or disease	Intervention/treatment	Phase
Leukemia; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)	Drug: Azacitidine; Drug: Lenalidomide	Phase 2

Detailed Description:

This is an open label, single-center, and phase 2 study of the combination of azacitidine with lenalidomide in previously treated elderly patients with acute myeloid leukemia (AML) and/or high-risk myelodysplastic syndrome (MDS) who have failed prior therapy with either a demethylating agent and/or IMIDs. MDS includes Chronic Myeloid Leukemia (CML).

Participants patients will receive azacitidine on the first 7 days followed by lenalidomide. Disease assessments with bone marrow examinations will be performed and if a complete response (CR); Complete remission with incomplete count recovery (CRi); partial response (PR); or stable disease (SD) is documented after 6 total cycles, participants will continue treatment until evidence of disease progression, provided they are tolerating treatment. Participants who have progressive disease or relapsed disease after the 6th cycle will be taken off the study, and participants with excessive toxicity at any time will be taken off the study.

• CR = Less than 5% blasts with no Auer rods, absence of extramedullary disease, absolute neutrophil count (ANC) > 1000/µL, platelets > 100,000/µL, and independence of red cell transfusion)
• CR with incomplete recovery (CRi) = all criteria of a CR with the exception of a platelet count less than 100,000/µL or residual neutropenia (< 1000/µL).
• PR = Meeting all hematologic criteria for CR with an allowance for 5% to 25% bone marrow blasts or decrease of pretreatment bone marrow blast percentage by ≥ 50%.
• SD = Change in bone marrow aspirate blast count within 10% of baseline.
• PD = Progressive / relapsed disease defined as reappearance of blasts in the blood or bone marrow blasts ≥ 5%, and development of extramedullary disease.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 33 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Azacitidine Plus Lenalidomide Combination in Elderly Patients With Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS) (VIREL2 Trial)
• Study Start Date: August 2011
• Actual Primary Completion Date: March 2014
• Actual Study Completion Date: May 2014

Arms and Interventions

Arm

Intervention/treatment

Experimental: Azacitidine plus Lenalidomide; Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.

Drug: Azacitidine; Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death; Other Names: 5-azacytidine; Vidaza; Drug: Lenalidomide; Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.; Other Names: CC-5013; Celgene; Revlimid

Outcome Measures

Primary Outcome Measures :

1. Overall Response Rate (ORR) [ Time Frame: 203 days ]
   Overall response rate was defined as the sum of Complete Response (CR) + CR with incomplete count recovery (CRi) + Partial Response (PR).

Secondary Outcome Measures :

1. Median Duration of Response [ Time Frame: 203 days ]
   The median duration of response was defined by the median duration of response for participants with Complete Response (CR); CR with incomplete count recovery (CRi); or Partial Response (PR).
2. Overall Survival [ Time Frame: 462 Days ]
   Survival was measured from the 1st day of azacitidine treatment to death from any cause.

Eligibility Criteria

• Ages Eligible for Study: 60 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• acute myeloid leukemia (AML) (according to the WHO 2008 classification):

  • De novo
  • Secondary AML previously treated with demethylating agents for AML
  • Secondary AML previously treated with demethylating agents for MDS
  • Secondary AML previously treated with high dose lenalidomide for AML (≥ 25mg)

• High Risk MDS:

  • Del (5q)
  • Non-del (5q), previously-treated with lenalidomide.
  • Novo or secondary HR-MDS previously treated with demethylating agents
• White blood cell (WBC) ≤ 10,000
• Age ≥ 60
• Not an immediate candidate for allogeneic stem cell transplantation
• Unwilling or unable to receive conventional chemotherapy

• Prior therapy:

  • with single agent demethylator (5-Azacitidine or Decitabine)
  • with Lenalidomide
• Eastern Cooperative Oncology Group performance status ≤ 2
• Life expectancy > 2 months
• All study participants must be registered into the mandatory RevAssist program
• Willing and able to comply with the requirements of RevAssist

• Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test 10-14 days prior to study enrollment and again within 24 hours of prescribing lenalidomide

  • Must commit to either continued abstinence from intercourse or begin two acceptable methods of birth control, at least 28 days before she starts taking lenalidomide.
  • Must also agree to ongoing pregnancy testing.
• Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
• Willing and able to understand and voluntarily sign a written informed consent
• Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

• Patients with LR-MDS progressing to HR-MDS after low dose lenalidomide or 5-day azacitidine will not be eligible.

• History of intolerance to thalidomide

  -development of erythema nodosum while taking thalidomide or similar drugs

• Known or suspected hypersensitivity to azacitidine or mannitol
• Patients with advanced malignant hepatic tumors.
• Concomitant treatment with other anti-neoplastic agents, with the exception of hydroxyurea
• Previous participation on the VIREL study with the concomitant use of azacitidine plus lenalidomide.
• Anti-neoplastic treatment less than four weeks prior to enrollment, with the exception of hydroxyurea
• Use of any other experimental drug or therapy within 28 days of baseline
• Inability to swallow or absorb drug
• Active opportunistic infection or treatment for opportunistic infection within four weeks of first day of study drug dosing
• New York Heart Association Class III or IV heart failure
• Unstable angina pectoris
• Uncontrolled cardiac arrhythmia
• Uncontrolled psychiatric illness that would limit compliance with requirements
• Known HIV infection
• Pregnant
• Breast feeding
• Lactating females must agree not to breast feed while taking lenalidomide
• Other medical or psychiatric illness or organ dysfunction or laboratory abnormality

• Laboratory abnormalities:

  • Either creatinine ≥ 1.5 mg / dL or creatinine clearance ≤ 50 mL / min
  • Total bilirubin >1.5 x institutional ULN
  • AST and ALT > 2.5 x institutional ULN

Contacts and Locations

Locations

United States, California

Stanford University School of Medicine

Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Celgene Corporation

Investigators

• Principal Investigator: Bruno Carneiro de Medeiros; Stanford University

More Information

• Responsible Party: Bruno C. Medeiros, Associate Professor Medicine Hematology, Stanford University
• ClinicalTrials.gov Identifier: NCT01442714
• Other Study ID Numbers: IRB-21686; SU-08122011-8268 ( Other Identifier: Stanford University ); HEM0022 ( Other Identifier: OnCore Number ); VIREL2 ( Other Identifier: Stanford University )
• First Posted: September 28, 2011
• Results First Posted: January 3, 2018
• Last Update Posted: January 3, 2018
• Last Verified: December 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Myelodysplastic Syndromes; Neoplasms by Histologic Type; Neoplasms; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Lenalidomide; Azacitidine; Immunologic Factors; Physiological Effects of Drugs; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Antineoplastic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors